Lantheus Holdings, Inc. (LNTH): Operating Income
$310.83M
Year ended 2025-12-31
$302.34M
Trailing 12 months to 2026-06-30
+104.8%
3-year compound annual growth
+22.0%
10-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $310.83M | -32.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $456.98M | +25.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $364.64M | +907.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $36.20M | n/m | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | -$60.83M | n/m | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | -$4.20M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $51.66M | -19.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $64.49M | +24.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $51.85M | -8.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $56.59M | +33.1% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $42.53M | +7.9% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $39.42M | n/m | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | -$18.89M | n/a | 2016-03-02, From 2013-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $310.83M | -32.0% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | -$919.20M | n/m |
| Neogen Corp (NEOG) | 2026-05-31 | -$21.60M | n/m |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | -$387.20M | n/m |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.36B | +20.5% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$440.99M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$16.98M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $1.65M | n/m |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.91M | n/m |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗